课题基金 / 基金详情

Onset and biomarkers for progression of monoclonal gammopathies

Onset and biomarkers for progression of monoclonal gammopathies
单克隆丙种球蛋白病的发病和进展的生物标志物
批准号:
8846552
负责人:
SHAJI Kunnathu KUMAR
金额:
$32.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-17 至 2016-04-30

项目摘要

项目成果

SHAJI Kunnathu KUMAR的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):多发性骨髓瘤(MM)是一种危及生命的血液系统恶性肿瘤。尽管取得了重大进展,中位生存期仍然只有5年。骨髓瘤有一个长期的临床可检测的癌前阶段称为单克隆丙种球蛋白病的意义不明(MGUS),可以很容易地确定使用分泌的生物标志物单克隆免疫球蛋白(M蛋白)。还有一个中间临床阶段称为阴燃型多发性骨髓瘤(SMM)。SMM包括约50%的MGUS患者,这些患者患有克隆性但非恶性疾病,以及50%的早期MM患者,这些患者在生物学上已经发生恶性转化,但在临床上尚不明显。骨髓瘤在癌症中是独特的,因为发病率的种族差异很大;例如,年轻的黑人患这种疾病的风险比白人高3倍。其次,我们最近发现近亲中的发病率增加:一级亲属的MGUS风险高2-3倍。第三,尽管有一个中期SMM阶段,这是成熟的早期干预,我们在我们的能力,以防止骨髓瘤削弱,因为我们无法区分恶性疾病(MM)克隆非恶性疾病(MGUS),除非通过存在或不存在临床终末器官损伤。迫切需要能够可靠区分两者的生物标志物。我们已经确定了3个需要回答的基本问题:1)何时以及为什么MGUS起源?2)在黑人和一级亲属中风险增加的原因是什么?它能告诉我们关于这种疾病的病因学是什么?3)有哪些特异性生物标志物可以准确识别患有早期恶性肿瘤并因此注定在2年内进展为症状性MM的SMM患者?我们对MGUS,SMM和MM的理解做出了重大贡献,并准备好解决这三个关键问题。在目标1中,我们将通过研究来自12,540名年龄在10-49岁之间的患者的血液样本首次确定MGUS的发病和危险因素,这些患者代表了美国的分层随机抽样,少数民族比例过高。在目标2中,我们将研究MM患者一级亲属中MGUS的发病率和风险因素。在目标3中,我们将确定指示SMM中恶性转化存在的生物标志物,从而预测即将进展为症状性MM。我们相信我们的研究具有高度创新性,并将对我们理解MGUS的病因产生深远影响,种族差异和家族发病率增加的原因,并为恶性肿瘤的早期检测提供生物标志物。我们也相信我们的研究结果将从根本上改变这种疾病的早期诊断和治疗。
英文摘要
DESCRIPTION (provided by applicant): Multiple myeloma (MM) is a life-threatening hematologic malignancy. Despite major advances, median survival is still only 5 years. Myeloma has a long clinically detectable premalignant phase called monoclonal gammopathy of undetermined significance (MGUS) that can be identified easily using the secreted biomarker monoclonal immunoglobulin (M protein). There is also an intermediate clinical stage referred to as smoldering multiple myeloma (SMM). SMM consists of approximately 50% of patients with MGUS who have clonal but nonmalignant disease and 50% of patients with early stage MM in whom the malignant transformation has occurred biologically but is not yet clinically apparent. Myeloma is unique among cancers because of the dramatic racial disparity in incidence; young blacks for example have a 3 fold higher risk of the disease than whites. Second, there is an increased incidence in close relatives that we have recently identified: first degree relatives hav a 2-3 fold higher risk of MGUS. Third, despite having an intermediate SMM stage that is ripe for early intervention, we are crippled in our ability to prevent myeloma since we are unable to discriminate malignant disease (MM) from clonal non malignant disease (MGUS) except through the presence or absence of clinical end-organ damage. Biomarkers that can reliably distinguish the two are critically needed. We have identified 3 fundamental questions that need to be answered: 1) When and why does MGUS originate? 2) What is the reason for the increased risk in blacks and in first degree relatives and what can it teach us about the etiology of the disease? 3) What are the specific biomarkers that can accurately identify SMM patients who have early malignancy and therefore destined to progress to symptomatic MM within 2 years? We have made major contributions to the understanding of MGUS, SMM, and MM and are well poised to address these 3 crucial questions. In Aim 1, we will determine for the first tim the onset and risk factors for MGUS by studying blood samples from 12,540 patients age 10-49 representing a stratified random sampling of the United States with overrepresentation of minorities. In Aim 2, we will study the incidence and risk factors for MGUS in first-degree relatives of patients with MM. In Aim 3, we will identify biomarkers that indicate the presence of malignant transformation in SMM, and thereby predict for imminent progression to symptomatic MM. We believe that our studies are highly innovative, and will have a far-reaching impact on our understanding of the etiology of MGUS, the reasons for the racial disparity and increased familial incidence, and provide biomarkers for early detection of malignancy. We also believe our results will fundamentally alter the early diagnosis and treatment of this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Cereblon Pathways in Myeloma
  • 批准号:
    9024349
  • 项目类别:
  • 资助金额:
    $44.63万
  • 财政年份:
    2014
  • 负责人:
    SHAJI Kunnathu KUMAR
  • 依托单位:
The Role of Cereblon Pathways in Myeloma
  • 批准号:
    8669613
  • 项目类别:
  • 资助金额:
    $49.46万
  • 财政年份:
    2014
  • 负责人:
    SHAJI Kunnathu KUMAR
  • 依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
  • 批准号:
    8342326
  • 项目类别:
  • 资助金额:
    $32.99万
  • 财政年份:
    2012
  • 负责人:
    SHAJI Kunnathu KUMAR
  • 依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
  • 批准号:
    8512677
  • 项目类别:
  • 资助金额:
    $31.01万
  • 财政年份:
    2012
  • 负责人:
    SHAJI Kunnathu KUMAR
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: